Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors

16 May 2013

Abstract excerpt

Ganglioside GD2 is a cell surface glycolipid that is highly expressed on cancer cells of neuroectodermal origin, including neuroblastoma, retinoblastoma, melanoma, sarcomas, brain tumors and small cell lung cancer. Monoclonal antibodies (MoAb) that target GD2 have shown clinical efficacy in the treatment of GD2 expressing tumors, and are expected to be the new standard of care for the treatment of pediatric...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Glycosylation and Glycoproteins Research
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23696816
DOI: 10.1371/journal.pone.0063359

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive TumorsPMID 23696816Read ↗

Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.Semantic proximity Read ↗

Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3.Semantic proximity Read ↗

Structure-guided computational design and mechanistic understanding of the p95HER2-targeting NAZ-mAb antibody and its variantsSemantic proximity Read ↗

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read ↗

Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity TargetingSemantic proximity Read ↗

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersSemantic proximity Read ↗

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.Semantic proximity Read ↗

Affinity maturation of antibodies assisted by in silico modeling.Semantic proximity Read ↗

Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma.Semantic proximity Read ↗

Affinity maturation and characterization of the ofatumumab monoclonal antibody.Semantic proximity Read ↗

Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumorsSemantic proximity Read ↗

Engineering affinity-matured variants of an anti-polysialic acid monoclonal antibody with superior cytotoxicity-mediating potencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.